🔗 Share this article

While the US continues making historic revisions to its vaccination recommendations, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations throughout the pandemic and has focused upon potential fatalities following Covid immunization in her recent time at the Food and Drug Administration.

Planned Shifts to Childhood Immunization Program

Health officials planned to announce sweeping revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with a large portion of the global community with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to address the audience at the event. She was just designated acting director of the FDA’s CDER, the fifth person to run the center this year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the drug and biologics centers as Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for ending some childhood vaccine recommendations in the US in order to be more like the Danish model, a country with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible background in pharmaceutical research, oversight or leadership, which has been typical for past directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the CDER, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in managing a major agency. She has no expertise in industry regulation.”

Former directors of the center would “understand laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

The drug center has an immense workload at the agency, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and every single one need to be looked after,” Woodcock explained. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a major administrative aspect to the role, which supervises over 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” the former official concluded.

Agency Reaction and Contentious Initiatives

Regarding questions about Høeg’s credentials and whether this assignment represents greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “questions rely on inaccurate assumptions”.

“This background aligns with the functions of her job,” the official explained, citing the time Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched expedited review system, a controversial one-day drug-approval program that reportedly worried her former heads. “By what process are these drugs being selected for this fast-track system? Who is making the choices?” Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of most medications, aside from immunizations.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, history, critics observe. She released a analysis using non-validated crowd-sourced reports to determine the incidence of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the new administration encompassed altering regulations for recently developed shots and halting “unnecessary” vaccines, she said post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She’s an complete ideologue who starts off with her beliefs and reverse-engineers to retrofit the science in a highly misleading, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|